What is Novocure?
Novocure is a specialized oncology enterprise dedicated to extending survival rates for patients diagnosed with some of the most aggressive forms of cancer. The company's core innovation, Tumor Treating Fields, represents a paradigm shift in cancer treatment, utilizing electric fields to disrupt cancer cell division. With commercialized products already approved for glioblastoma and malignant pleural mesothelioma in key international markets, Novocure is actively expanding its clinical footprint. The firm maintains a robust research and development pipeline, with ongoing investigations into brain metastases, gastric cancer, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. Headquartered in Jersey with a sprawling operational presence across the United States, Germany, Switzerland, Japan, and Israel, Novocure integrates advanced medical engineering with global clinical reach.
How much funding has Novocure raised?
Novocure has raised a total of $708M across 3 funding rounds:
Stock Offering
$158M
Debt
$150M
Debt
$400M
Stock Issuance/Offering (2015): $158M with participation from Undisclosed
Debt (2018): $150M led by BioPharma Credit PLC
Debt (2024): $400M supported by Pharmakon Software
Key Investors in Novocure
Pharmakon Software
Pharmakon Software GmbH specializes in omnichannel CRM and digital sales solutions tailored for the pharmaceutical and life sciences sectors, focusing on operational efficiency and compliance.
BioPharma Credit PLC
A specialized investment firm providing debt financing solutions to life sciences companies to support clinical development and commercial growth.
Undisclosed Investors
What's next for Novocure?
With the recent influx of capital, Novocure is well-positioned to accelerate its clinical trial roadmap and enhance its commercial infrastructure. The strategic focus will likely center on the successful execution of late-stage trials and the potential expansion of Tumor Treating Fields into new therapeutic indications. As the company navigates the complexities of global regulatory environments, this financing provides the operational runway required to scale manufacturing and distribution capabilities. Investors and stakeholders are closely monitoring the company's ability to translate its innovative research into broader market adoption, which remains the primary driver for long-term value creation in the competitive oncology landscape.
See full Novocure company page
